Review

Neuroimmunomodulation by estrogen in health and disease

Hannah P Priyanka* and Rahul S Nair

Inspire Laboratory, Institute of Advanced Research in Health Sciences, Tamil Nadu Government Multi Super Speciality Hospital, Omandurar Government Estate, Chennai-600002, India

* Correspondence: Email: hannahpriyanka@gmail.com; Tel: 914425666620.

Abstract: Systemic homeostasis is maintained by the robust bidirectional regulation of the neuroendocrine-immune network by the active involvement of neural, endocrine and immune mediators. Throughout female reproductive life, gonadal hormones undergo cyclic variations and mediate concomitant modulations of the neuroendocrine-immune network. Dysregulation of the neuroendocrine-immune network occurs during aging as a cumulative effect of declining neural, endocrine and immune functions and loss of compensatory mechanisms including antioxidant enzymes, growth factors and co-factors. This leads to disruption of homeostasis and sets the stage for the development of female-specific age-associated diseases such as autoimmunity, osteoporosis, cardiovascular diseases and hormone-dependent cancers. Ovarian hormones especially estrogen, play a key role in the maintenance of health and homeostasis by modulating the nervous, endocrine and immune functions and thereby altering neuroendocrine-immune homeostasis. Immunologically estrogen’s role in the modulation of Th1/Th2 immune functions and contributing to pro-inflammatory conditions and autoimmunity has been widely studied. Centrally, hypothalamic and pituitary hormones influence gonadal hormone secretion in murine models during onset of estrous cycles and are implicated in reproductive aging-associated acyclicity. Loss of estrogen affects neuronal plasticity and the ensuing decline in cognitive functions during reproductive aging in females implicates estrogen in the incidence and progression of neurodegenerative diseases. Peripherally, sympathetic noradrenergic (NA) innervations of lymphoid organs and the presence of both adrenergic (AR) and estrogen receptors (ER) on lymphocytes poise estrogen as a potent neuroimmunomodulator during health and disease. Cyclic variations in estrogen levels throughout reproductive life, perimenopausal surge in estrogen levels followed by its precipitous decline, concomitant with decline in central hypothalamic catecholaminergic activity, peripheral sympathetic
NA innervation and associated immunosuppression present an interesting study to explore female-specific age-associated diseases in a new light.

**Keywords:** neuroendocrine; norepinephrine; 17 $\beta$-estradiol; neural-immune; immunosenescence; reproductive aging; autoimmunity

1. **Introduction**

Homeostatic functions at the cellular and systemic level are maintained by cross-talk between the nervous system, endocrine system and immune system. This reciprocal communication among the homeostatic systems is essential for the maintenance of health, and any dysregulation in the communication leads to susceptibility and development of disease [1,2]. Through several studies, it has been established that the hormonal secretion from the pituitary is tightly regulated by the hypothalamic neuroendocrine system through the release of hormones, neurotransmitters and neuropeptides; targeting endocrine glands to influence psychological and physiological functions including immunity [1,3]. The immune system in turn also regulates systemic functions, through release of cytokines and chemokines that can cross the blood-brain barrier and thus, regulate the neural functions in the brain [4]. In addition to the indirect effects on immune functions, the nervous system can directly influence immune functions through synaptic associations of sympathetic NA and peptidergic nerve fibers by the release of norepinephrine (NE) and neuropeptides, respectively that innervate the primary and secondary lymphoid organs [5].

Aging is marked by decline in homeostatic maintenance in the neuroendocrine-immune network. Several studies have reported that age-associated dysregulation in the cross-talk between the neuroendocrine and immune system contributes to the development of diseases, in both rodents and humans [1,2,5,6]. Aging in women, as compared to men, is different, evident by the distinct changes in the release of hormones and reproductive cyclicity, which in turn enhances the risk of development of female-specific diseases such as autoimmune disorders, hormone-dependent cancers, osteoporosis etc [7–9]. The crucial changes in hormonal secretion and reproductive cyclicity occur during middle age in both rodents and women, as they transition into acyclicity and menopause, respectively [3,10,11]. The menopausal transition is characterised by an early phase with delayed cycles and a late phase with more than 60 days of amenorrhea followed by a period of less frequent cycling and the final menstrual period spanning over a decade [12]. Estrogen levels surge during the early menopausal transition followed by a rapid decline spanning a period of 2 years before the final menstrual period is achieved and the levels stabilise again [12–14]. Thus the transition from regular cycles to menopause is a gradual process of hormonal changes that span multiple years, during which central and systemic functions are chronologically adapted to effect metabolic, immunological and neurological modulations.
2. Neuromodulation by estrogen

In females, reproductive aging is one of the first hallmarks of age-associated decline in the neuroendocrine-immune network. The depletion of ovarian follicles, hypothalamic deficits and the ensuing decline in the hypothalamic-pituitary-gonadal (HPG) axis and its mediators involving neurotransmitters, neuropeptides, releasing hormones [gonadotropin releasing hormone (GnRH) and luteinizing hormone (LH)] and target organs (ovaries) lead the transition into menopause [1,3,15]. This transition in females, begins during middle age before the onset of irregular cycles and a decline in GnRH-positive (GnRH⁺) neurons by a reduction in the ability of estrogen to induce neurochemical changes associated with pre-ovulatory surge in GnRH and LH [15–17]. Changes in the timing of the pre-ovulatory surges during middle age may be traced back to circadian rhythm disruptions due to deficits in the neurons of the hypothalamic suprachiasmatic nucleus [16]. The ability of estrogen to elicit GnRH/LH surge is attenuated much earlier than the actual reduction in GnRH⁺ neurons in the hypothalamus through decline in hypothalamic stimulatory molecules such as glutamate, NE, vasoactive intestinal peptide (VIP) and increase in inhibitory signals such as gamma-amino butyric acid (GABA) and opioids [3]. Proestrus spike in NE levels and tyrosine hydroxylase (TH) activity in the medial preoptic area and the arcuate nucleus were not observed in young and old dioestrus rats implicating estrogen-induced LH surge in central neurotransmitter release [17–21]. Thus centrally, estrogen plays a crucial role in the maintenance of neuroendocrine homeostasis in young females by inducing hypothalamic neurons and regulating the hormonal outflow through neurotransmitters and neuropeptides. The presence of estrogen seems vital in the maintenance of hypothalamic and hippocampal neurons that decline with reproductive age thereby highlighting the neuroprotective role of estrogen on central neurons by mediating antioxidant and antiapoptotic effects, modulating neurotrophic signals and promoting crosstalk. Peripherally however, the results are contradictory. The neuroprotective role of estrogen has been well established and yet, the perimenopausal estrogen surge in rodents has been shown to be implicated in the loss of sympathetic NA innervation of lymphoid organs leading to disruption in neuroendocrine-immune homeostasis in the periphery [22,23]. Treatment of ovariectomised middle-aged Sprague-Dawley (SD) rats with estrogen [0.6 µg and 300 µg timed-sustained release (SR) pellets/30 days] significantly decreased the expression of p-TH in the mesenteric lymph nodes [24]. The onset of menopause is characterised by a dramatic decline in circulating levels of estrogen leading to a hypoestrogenic state that have lasting implications on the reproductive and non-reproductive functions of the hormone ranging from loss of rhythmicity in neurotransmitter dynamics in the brain to a decline in peripheral immune responses [25,26]. Thus in the periphery, the estrogen surge in the perimenopausal/early transition phase is implicated in the loss of sympathetic nerve fibers in the lymphoid organs leading to dysregulation of neural-immune homeostasis. The effects of estrogen can perhaps be understood from a dose-response perspective. The higher circulating levels during menopausal transition in the periphery may be neurodegenerative although centrally, estrogen seems to exert a neuroprotective role.
3. Immunomodulation by estrogen

In women, regular menstrual cycles in the young give way to irregular cycles by middle-age, leading to perimenopausal estrogen surge, onset of menopause leading to the final menstrual period. Rhythmic cyclicity of ovarian hormones including estrogen are implicated in the alteration of cell-mediated immune responses in follicular and luteal phases of the menstrual cycle. Cell-mediated immune functions including mitogen-induced proliferation and cytokine production were significantly enhanced during follicular phase of the menstrual cycle in young women compared to the luteal phase [25]. In the lymphoid organs, estrogen is involved in the regulation of maturation, differentiation, activation and proliferation of lymphoid cells thereby influencing immune effector molecules like cytokines and antibodies [27]. Estrogen modulates Th1/Th2 cytokine balance in favour of Th2 type and influences humoral responses to diseases [28–29]. In murine models, estrus cycle-associated fluctuations in the levels of circulating gonadal hormones have been shown to alter T and B cell proliferation, and localization of immunoglobulin-A (IgA)-producing plasma cells [30]. Immunomodulation by estrogen is concentration dependent and varies according to the nature of the immune stimulus, the receptor subtype profile of the target organ, and the timing of administration [31–34]. Preovulatory surge in estrogen inhibits the translocation of nuclear factor-kappa B (NF-kB) through transcriptional repression of Ikbkg and affect the maturation of dendritic cells in the lymph nodes [32]. On the other hand, low dose estrogen treatment of ovariectomised rats enhanced interferon-gamma (IFN-γ) production and antigen-specific T cells [33,34]. Thus it is implicated in the predominant incidence of autoimmune diseases, hormone-dependent cancer, osteoporosis, and cardiovascular diseases through alterations in T cell functions and cytokines during reproductive aging in females [35–37]. Centrally, estrogen mobilises astrocytes and microglia and plays a neuroprotective and anti-inflammatory role through neurotrophin-mediated growth, survival and neuronal plasticity [38–40]. Hypothalamic neuronal deficits and peripheral sympathetic denervation share a cause-effect relationship with age-associated decline in estrogen and associated immunosuppression [9,18,19,22]. Thus estrogen plays a clearly defined role in influencing the immune responses in women depending upon the phase of menstrual cycle, reproductive age, levels of circulating estrogen, and influences the type of response elicited by modulating the Th1/2 balance.

4. Estrogen-mediated reversal of adrenergic immunosuppression

The presence of sympathetic NA nerve fibres in synaptic association with immune organs, and the expression of adrenergic and steroid hormone receptors on immune cells renders immune cells susceptible to the immunomodulatory effects of both neurotransmitters and steroid hormones alike. Of interest here is the interesting crosstalk between NE signals released from the sympathetic fibres and circulating estrogen, both of which have shown contradictory effects on immune cells.

The expression of adrenergic receptor (AR) subtypes including α1-, α2-, β1-, β2- adrenoceptors have been characterised in several immune cell subsets including splenic lymphocytes (T cells and B cells) and natural killer (NK) cells [2]. Published data from our laboratory has shown that predominantly, adrenergic stimulation of splenic lymphocytes is immunosuppressive. Treatment of
splenocytes with α1-AR agonist phenylephrine, significantly decreased splenocyte IFN-γ expression (10^{-3} M, 10^{-6} M and 10^{-9} M) while α2-AR agonist clonidine (10^{-6} M and 10^{-9} M) inhibited splenocyte proliferation, phosphorylated-extracellular signal regulated kinase (p-ERK) and phosphorylated-cAMP response element binding protein (p-CREB) expression [41]. β2-AR agonist terbutaline (10^{-6} M and 10^{-9} M) significantly decreased splenocyte proliferation and interleukin-6 (IL-6) expression in splenic lymphocytes [42]. Estrogen co-treatment significantly reverses immunosuppression by α1-, α2-, and β2- adrenoceptor agonists. Co-treatment of splenocytes with 10^{-9} M 17β-estradiol reverses phenylephrine-mediated decline in IFN-γ expression, clonidine-mediated decline in proliferation, p-ERK and p-CREB expression and terbutaline-mediated decline in proliferation and IL-6 expression [41,42]. 1-ARs are expressed on neutrophils, mast cells, macrophages, dendritic cells and microglia where they are known to mediate inhibition of neutrophil functions, mast cell histamine release, macrophage tumor necrosis factor-alpha (TNF-α) expression, dendritic cell migration and suppression of microglial activation [43–47]. Unpublished data from our laboratory has shown that coincubation of splenic lymphocytes with 1-AR agonist dobutamine, suppresses splenocyte proliferation thereby exerting a similar immunosuppressive effect. These studies have shown that sympathetic modulation of immune cell functions may be crucial for the maintenance of naïve cells in the lymphoid organs. Exposure to estrogen overrides the immunosuppressive role of NE and stimulates immune functions. Reproductive aging is associated with concomitant loss of sympathetic NA fibers and associated naïve cells possibly due to compounded effect of prolonged exposure to circulatory estrogen throughout reproductive life and estrogen surge during early menopausal transition.

5. Mechanistic role of ERs

Intracellular (genomic and non-genomic) effects of estrogen are mediated by specific intracellular and membrane receptors namely ERα and ERβ. ERα is predominantly expressed on CD4+ T cells while ERβ predominantly expressed on B cells, playing a role in maturation and differentiation of thymic T cells and B lymphopoiesis in the bone marrow [48]. Once estrogen binds to these receptors, they control the expression of their target genes by binding to the estrogen response element (ERE) leading to the activation of several downstream signals including NF-κB, activator protein-1 (AP1) or ERK [48–49]. Studies from our laboratory have shown that, the effects of estrogen on cell mediated immune functions are concentration dependent and are differentially mediated through specific receptor subtypes through antioxidant enzymes and nitric oxide (NO) [34]. Thus the effects of estrogen on cell-mediated immune functions may be dependent upon the type of immune cells and mediated through ERα and ERβ [50,51]. ERα mediates the expression of Th1 cytokines and proliferation of CD4+ T cells in normal rodents and experimental autoimmune disease model of myasthenia gravis [33,52]. ERα-mediated suppression of NF-κB through regulation of let-7a and miR-125b microRNAs have been shown to play a role in estrogen-mediated suppression of inflammatory process in primary macrophages [53,54]. Expression of ERα-mediated signals in the splenocytes has been implicated in the suppression of inflammation in trauma-haemorrhage through IL-6 and TNF-α [55]. These studies have shown that ERα plays a predominantly anti-inflammatory role favouring Th1 responses and suppressing inflammatory signals. The involvement of both ERα/β have been shown in protection against bacterial infection and sepsis in
an animal model of trauma-haemorrhage by reversing the suppression of T cell proliferation and inducing Th1 and Th2 cytokine production [56,57]. In mouse models of cardiotoxin-induced myoinjury, estrogen exerts anti-inflammatory effects through infiltration of anti-inflammatory M2-macrophages and T-regulatory cells and suppressing Th1 responses through ERβ [58]. Estrogen can exert its effects across immune cell subsets through receptor-dependent and receptor independent mechanisms and mediate specific effects [59].

Crosstalk between estrogen and adrenergic signalling has also been implicated in the expression of proinflammatory cytokines by peritoneal macrophages [60]. In an in vitro study conducted in our laboratory, estrogen [10^{-6} M] treatment of splenic lymphocytes reversed immunosuppression mediated by adrenergic agonists and enhanced cell-mediated immune functions [41,42]. Apart from ERs, estrogen can also bind to membrane-bound G protein-coupled estrogen receptor (GPER) and regulate T cell mediated immune functions [61]. ER-mediated activation of ERK/mitogen activated protein kinase (MAPK), CREB, and Akt pathways have been shown in MCF-cells, immortalised neuronal cultures, Parkinson’s disease and glioma models [62–65]. Estrogen has been shown to modulate the tumor-immune microenvironment in female mouse models of liver cancer through ERα and ERβ [66].

Centrally, the effects of estrogen are transduced through the activation of ERK and CREB in the hypothalamus and hippocampus, activation of Akt signalling pathways in the striatum or mediating anti-inflammatory effects through inhibition of NF-κB [67–73]. Estrogen augments TH promoter activity through specific pathways involving membrane-bound ERα in PC-12 neuronal cells and ERβ in mouse locus coeruleus [74–76]. The expression of ERβ and ERα in the adult female brain is significantly altered with reproductive age and estrogen supplementation in specific brain areas and their relative expression may modulate downstream signalling responses in order to influence memory, cognitive functions, neuronal plasticity, inflammation and neurodegeneration [77,78]. Evidence from estrogen replacement therapy studies has shown that the synthetic steroid, Tibolone with weak estrogenic, progestogenic and androgenic activity decreased body weight, glucose tolerance, triglycerides and cholesterol levels in SD rats fed with high-fat high-fructose diet compared to standard diet by modulating the expression of ERs in the brain area [79]. Thus estrogen can influence neuroimmunomodulation both centrally and peripherally through specific intracellular pathways based on the dose, type of receptor subtype activated and presence of co-stimulatory/inhibitory signals.

6. **Estrogen and neuroprotection**

The role of 17 β-estradiol in neuroprotection in young and old females has been widely explored in a number of studies. We have shown that estrogen exerts a dual role by mediating neuroprotective effects in specific brain areas while causing sympathetic denervation in the periphery esp. lymphoid organs [22,25]. Administration of a single dose of 17 β-estradiol (10 pg/kg s.c.) or using SR pellets (0.1 pg/pellet/3 weeks), to ovariectomised adult virgin female SD rats similar to proestrus surge in estrogen have both shown significantly decreased sympathetic innervation in the uterine smooth muscles [80]. Similarly, ovariectomised adult female Long Evans hooded rats treated with estrogen dose of 40–55 μg/kg/d orally up to 8 months showed increased TH-positive (TH⁺)
nerve fibers in the medial prefrontal cortex of old rats [81]. In our study, ovariectomised middle-aged female SD rats supplemented with estrogen through SR pellets implanted at the scruff (300 µg) for 30 days showed increased splenic p-TH and nerve growth factor (NGF) expression [82]. However, estrogen (0.6 µg) supplementation of ovariectomised middle-aged SD rats enhanced TH expression in frontal cortex and hippocampus, suppressed NF-κB expression in the frontal cortex and striatum, and decreased NGF expression in the hippocampus [83,84]. Long-term effects of estrogen exposure in the periphery are implicated in the early onset of peripheral sympathetic denervation of lymphoid organs in females compared to males [22]. Age-associated decline in estrogen is concomitant with the development of cognitive impairment and neurodegenerative diseases through decline in basal forebrain neurons, inhibition of NO and cholinergic functions, loss of trophic factors and onset of neuroinflammation [72,73,83–89]. Estrogen plays a neurotrophic role promoting plasticity in hippocampal neurons through expression of growth factors, signalling molecules, cholinesterases and boosting metabolism [73,90–91]. Estrogen-induced synthesis of catecholamines through modulation of TH+ fiber density and TH activity in the hippocampus and frontal cortex have been implicated in memory and cognitive functions [73,92–95]. The trophic effects of estrogen begins early in the brain development showing neuroprotective effect that may modulate neurodevelopment of different brain structures as evident with studies reporting differences in men and women with movement disorders [96]. Central neuroprotective effects of estrogen clearly substantiate the claim that estrogen is beneficial for the brain. However, neuroprotection by estrogen cannot be extrapolated to the periphery which is exposed to fluctuating levels of estrogen throughout reproductive life and during menopausal transition.

7. Estrogen and the antioxidant machinery

Aging takes a toll on cellular processes through increased allostatic load of reactive oxygen species and decline in antioxidant machinery leading to impaired functions and cellular distress. Peroxides and superoxide anions can bind to cell membrane lipids through malondialdehyde adducts leading to impaired structural integrity that eventually compromise functional integrity of the cell [97,98]. Collectively, these changes affect neuroendocrine-homeostasis leading to dysregulation and development of age-associated diseases. Studies using splenic lymphocytes from old rats have shown age-associated increase in lipid peroxidation, accumulation of protein carbonyl compounds leading to enzyme dysfunctions, disruption of cellular functions and immunosenescence [73,81,99]. Estrogen (10^{-12} M, 10^{-10} M and 10^{-8} M) plays a potent antioxidant function in splenic lymphocytes by increasing the activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) in vitro [34]. Ovariectomised female rats showed significantly reduced chemotaxis index, lymphocyte proliferation and NK cell activity compared to their age-matched and young controls [82,100–102]. In ovariectomised animals supplemented with estrogen through SR pellets (0.6 and 300 µg) for 30 days, there was a significant reversal of age-associated decline in antioxidant enzyme activities and accumulation of reactive oxygen species, lipid peroxides and protein carbonyls in lymphoid organs and brain areas [73,82]. Physiological levels of estrogen may promote female longevity through the upregulation of antioxidant signals through survival signalling (MAPK, ERK) or anti-inflammatory signalling (NF-κB) cascades both
centrally and peripherally [25,103]. Further, estrogen confers protection against mitochondrial stress, and ERα has been linked to mitochondrial unfolded protein response [UPR (mt)], that orchestrates several pathways, including antioxidant machinery [104]. In the brain, estrogen-mediated neuroprotective effects in healthy aging, cerebral ischemia and Alzheimer’s disease also involve its potent ability to suppress cellular oxidative stress by enhancing antioxidant activities in various brain regions [68,105–106]. Antioxidant effects of estrogen play a crucial role in neuroimmunomodulation in the periphery thereby enhancing immune cell functions and neuronal integrity, suppressing inflammation and maintaining neural-immune homeostasis in the young and in healthy aging.

8. Estrogen and energy metabolism

The brain is a glucose-intensive organ and hence places a huge physiological demand for energy currency on the systemic metabolic process [107]. Estrogen plays a crucial role in meeting this demand by upregulating the expression of glucose transporters to facilitate glucose transport across the blood brain barrier, enhancing the glycolytic process by influencing p53, glycolytic enzymes and regulation of the tricarboxylic acid (TCA) cycle and enhancing mitochondrial integrity [108–112]. Estrogen can modulate the expression and activity of specific isozymes of glycolytic enzymes such as hexokinase, phosphofructokinase and pyruvate kinase in rat neuronal cells [113,114]. Hormone replacement studies in women undergoing perimenopause, early menopause and surgical menopause have shown that estrogen enhances glucose metabolism in the brain, attenuates neuroinflammation and prevents cognitive decline [115–119].

Another target of estrogen is the Na+/K+/ATPase pump that is energy intensive and is crucial for the maintenance of ionic gradients, resting potentials and triggering action potentials that is also regulated by catecholamines mainly NE and serotonin (5-HT) [110,111]. Estrogen treatment of ovariectomised female SD rats enhances the activity of Na+/K+/ATPase activity in the frontal cortex and hypothalamus conferring neuroprotection against amyloid-β-induced oxidative stress and suppressing lipid peroxidation [120,121]. During aging and in age-associated degenerative diseases such as Alzheimer’s and Parkinson’s, there is a decline in mitochondrial regulation of oxidative phosphorylation primarily due to cytochrome C oxidase leading to an energy-defunct state that aids in the progressive degeneration [112,122,123]. Estrogen treatment enhanced the activity of cytochrome C oxidase in the frontal cortex, medial basal hypothalamus and hippocampus and promoted neuronal activity [124]. Thus the regulators of energy metabolism, mitochondrial integrity and transporters by estrogen plays a crucial role in the etiology and pathology of these diseases [125,126].

9. Conclusions

The diverse effects of estrogen on the neuroendocrine network and the dependence of the female physiology on the robustness of estrogen-associated regulatory functions during reproductive life and aging places women at risk of developing autoimmune diseases, heart diseases, osteoporosis, neurodegenerative diseases, and breast cancer. While loss of neuroendocrine-immune homeostasis shares a cause-effect relationship with impaired hormone secretion, immunosenescence, peripheral denervation and central neurodegeneration, decline in neurotransmitters etc, the cumulative effects
set the stage for age-associated disease pathology (Figure 1). Age-associated disruption of neuroendocrine-immune homeostasis is exacerbated by dysfunctional antioxidant machinery, increased allostatic load, decline in biosynthesis of trophic factors, signal transduction molecules and poor energy metabolism. Although loss of estrogen precludes the deregulation of neuroendocrine-immune homeostasis in females, the answer to restoring homeostasis isn’t as simple as estrogen replacement. This is due to the effects of estrogen as a double edged sword beneficial for neuroprotection in the central nervous system while mediating peripheral denervation in the lymphoid organs and enhancing the risk of cardiovascular diseases and breast cancer. Estrogen therefore is pivotal to the maintenance of homeostatic integrity in females and its effects are largely dependent upon the dose, time of secretion, nature of receptors and target organ. Mechanistic effects of estrogen may result in the transcription of genes regulated by specific response elements and contribute to a plethora of functions including cell-mediated immunity, Th1/Th2 cytokine balance, neuroprotection, growth factor biosynthesis, NE release, feed-back regulation of HPG axis, peripheral denervation, all of which may fuel the loop towards regulation or dysregulation in health and disease.

Figure 1. Estrogen levels rhythmically fluctuate throughout reproductive life. In young healthy females, the robustness of the neuroendocrine-immune network maintains physiological homeostasis by mutual regulation between the neural, endocrine and immune mediators. During reproductive aging however, perimenopausal surge in estrogen followed by its precipitous decline post menopause leads to neuroendocrine-dysfunction, peripheral denervation and immunosenescence compounded by the lack of trophic factors, neurotransmitters, signalling molecules and defunct antioxidant machinery.
Acknowledgement

Supported by the Department of Science and Technology, Government of India, New Delhi under the Inspire Faculty Award Scheme of AORC (IFA15/LSBM-154).

Conflict of interest

The authors declare no conflict of interest.

References

1. Meites J (1988) Neuroendocrine biomarkers of aging in the rat. *Exp Gerontol* 23: 349–358.
2. Bellinger DL, Lorton D, Lubahn C, et al. (2001) Innervation of lymphoid organs—Association of nerves with cells of the immune system and their implications in disease, In: Ader R, Felten DL, Cohen N, Author, *Psychoneuroimmunology*. 3Eds., San Diego: Academic Press, 1: 5–111.
3. Downs JL, Wise PM (2009) The role of the brain in female reproductive aging. *Mol Cell Endocrinol* 299: 32–38.
4. Banks WA (2015) The blood-brain barrier in neuroimmunology: tales of separation and assimilation. *Brain Behav Immun* 44: 1–8.
5. Bellinger DL, Millar BA, Perez S, et al. (2008) Sympathetic modulation of immunity: relevance to disease. *Cell Immunol* 252: 27–56.
6. ThyagaRajan S, Priyanka HP (2012) Bidirectional communication between the neuroendocrine system and the immune system: relevance to health and diseases. *Ann Neurosci* 19: 40–46.
7. Pratap U, Hima L, Kannan T, et al. (2020) Sex-Based Differences in the Cytokine Production and Intracellular Signaling Pathways in Patients With Rheumatoid Arthritis. *Arch Rheumatol* 35: i–xiii.
8. Hima L, Patel MN, Kannan T, et al. (2020) Age-associated decline in neural, endocrine, and immune responses in men and women: Involvement of intracellular signaling pathways. *J Neuroimmunol* 345: 577290.
9. ThyagaRajan S, Hima L, Pratap UP, et al. (2019) Estrogen-induced neuroimmunomodulation as facilitator of and barrier to reproductive aging in brain and lymphoid organs. *J Chem Neuroanat* 95: 6–12.
10. Randolph Jr JF, Sowers M, Bondarenko IV, et al. (2004) Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. *J Clin Endocrinol Metab* 89: 1555–1561.
11. Kermath BA, Gore AC (2012) Neuroendocrine control of the transition to reproductive senescence: lessons learned from the female rodent model. *Neuroendocrinology* 96: 1–12.
12. Harlow SD, Mitchell ES, Crawford S, et al. (2008) The ReSTAGE Collaboration: defining optimal bleeding criteria for onset of early menopausal transition. *Fertil Steril* 89: 129–40.
13. Wang Y, Mishra A, Brinton RD (2020) Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases. *F1000 Res* 9: 68.
14. Finkelstein JS, Brockwell SE, Mehta V, et al. (2008) Bone mineral density changes during the menopause transition in a multiethnic cohort of women. *J Clin Endocrinol Metab* 93: 861–868.
15. Brann DW, Mahesh VB (2005) The aging reproductive neuroendocrine axis. *Steroids* 70: 273–283.
16. Wise PM (2005) Estrogens and cerebrovascular stroke: what do animal models teach us? *Ann N Y Acad Sci* 1052: 225–232.
17. Wise PM, Scarbrough K, Lloyd J, et al. (1994) Neuroendocrine concomitants of reproductive aging. *Exp Gerontol* 29: 275–283.
18. MohanKumar PS, ThyagaRajan S, Quadri SK (1995) Cyclic and age-related changes in norepinephrine concentrations in the medial preoptic area and arcuate nucleus. *Brain Res Bull* 38: 561–564.
19. MohanKumar PS, ThyagaRajan S, Quadri SK (1997) Tyrosine hydroxylase and DOPA decarboxylase activities in the medial preoptic area and arcuate nucleus during the estrus cycle: effects of aging. *Brain Res Bull* 42: 265–271.
20. Wise PM (1982) Norepinephrine and dopamine activity in micro dissected brain areas of the middle-aged and young rat on proestrus. *Biol Reprod* 27: 562–574.
21. Wise PM (1984) Estradiol-induced daily luteinizing hormone and prolactin surges in young and middle-aged rats: correlations with age-related changes in pituitary responsiveness and catecholamine turnover rates in micro dissected brain areas. *Endocrinology* 115: 801–809.
22. ThyagaRajan S, Madden KS, Teruya B, et al. (2011) Age-associated alterations in sympathetic noradrenergic innervation of primary and secondary lymphoid organs in female Fischer 344 rats. *J Neuroimmunol* 233: 54–64.
23. Chakrabarti M, Haque A, Banik NL, et al. (2014) Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. *Brain Res Bull* 109: 22–31.
24. Ravichandran KA, Karrunanithi S, Hima L, et al. (2017) Estrogen differentially regulates the expression of tyrosine hydroxylase and nerve growth factor through free radical generation in the thymus and mesenteric lymph nodes of middle-aged ovariectomized female Sprague-Dawley rats. *Clin Exp Neuroimmunol* 8: 341–350.
25. Priyanka HP, Sharma U, Gopinath S, et al. (2013) Menstrual cycle and reproductive aging alters immune reactivity, NGF expression, antioxidant enzyme activities, and intracellular signalling pathways in the peripheral blood mononuclear cells of healthy women. *Brain Behav Immun* 32: 131–143.
26. Wise PM, Smith MJ, Dubal DB, et al. (2002) Neuroendocrine modulation and repercussions of female reproductive aging. *Recent Prog Horm Res* 57: 235–256.
27. Murray RW (2001) Estrogen, prolactin, and autoimmunity: actions and interactions. *Int Immunopharmacol* 1: 995–1008.
28. Salem ML (2004) Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. *Curr Drug Targets Inflamm Allergy* 3: 97–104.
29. Lang TJ (2004) Estrogen as an immunomodulator. *Clin Immunol* 113: 224–230.
30. Krzych U, Strausser HR, Bressler JP, et al. (1978) Quantitative differences in immune responses during the various stages of the estrus cycle in female BALB/c mice. *J Immunol* 121: 1603–1605.
31. Straub RH (2007) The complex role of estrogens in inflammation. *Endocr Rev* 28: 521–574.
32. Lasarte S, Elsner D, Sanchez-Elsner T, et al. (2013) Estradiol down regulates NF-κB translocation by Ikbkg transcriptional repression in dendritic cells. *Genes Immun* 14: 462–469.

33. Maret A, Coudert JD, Garidou L, et al. (2003) Estradiol enhances primary antigen- specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. *Eur J Immunol* 33: 512–521.

34. Priyanka HP, Krishnan HC, Singh RV, et al. (2013) Estrogen modulates in vitro T cell responses in a concentration- and receptor-dependent manner: effects on intracellular molecular targets and antioxidant enzymes. *Mol Immunol* 56: 328–339.

35. Maglione A, Rulla S, Mercanti SF, et al. (2019) The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View. *Cells* 8: 1280.

36. Ysrraelit MC, Correale J (2019) Impact of sex hormones on immune function and multiple sclerosis development. *Immunology* 156: 9–22.

37. Cutolo M, Sulli A, Capellino S, et al. (2004) Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. *Lupus* 13: 635–638.

38. Chakrabarti M, Haque A, Banik NL, et al. (2014) Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. *Brain Res Bull* 109: 22–31.

39. Babayan AH, Kramár EA (2013) Rapid effects of oestrogen on synaptic plasticity: interactions with actin and its signalling proteins. *J Neuroendocrinol* 25: 1163–1172.

40. Mónica Brauer M, Smith PG (2015) Estrogen and female reproductive tract innervation: cellular and molecular mechanisms of autonomic neuromodulation. *Auton Neurosci* 187: 1–17.

41. Priyanka HP, ThyagaRajan S (2013) Selective modulation of lymphoproliferation and cytokine production via intracellular signalling targets by α1- and α2-adrenoceptors and estrogen in splenocytes. *Int Immunopharmacol* 17: 774–784.

42. Priyanka HP, Pratap UP, Singh RV, et al. (2014) Estrogen modulates β2-adrenoceptor-induced cell-mediated and inflammatory immune responses through ER-α involving distinct intracellular signaling pathways, antioxidant enzymes, and nitric oxide. *Cell Immunol* 292: 1–8.

43. Scanzano A, Schembri L, Rasini E, et al. (2015) Adrenergic modulation of migration, CD11b and CD18 expression, ROS and interleukin-8 production by human polymorphonuclear leukocytes. *Inflamm Res* 64: 127–135.

44. Prey S, Leaute-Labreze C, Pain C, et al. (2014) Mast cells as possible targets of propranolol therapy: an immunohistological study of beta-adrenergic receptors in infantile haemangiomas. *Histopathology* 65: 436–439.

45. Du Y, Yan L, Du H, et al. (2012) β1-adrenergic receptor autoantibodies from heart failure patients enhanced TNF-α secretion in RAW264.7 macrophages in a largely PKA-dependent fashion. *J Cell Biochem* 113: 3218–3228.

46. Yang H, Du RZ, Qiu JP, et al. (2013) Bisoprolol reverses epinephrine-mediated inhibition of cell emigration through increases in the expression of β-arrestin 2 and CCR7 and PI3K phosphorylation, in dendritic cells loaded with cholesterol. *Thromb Res* 131: 230–237.

47. Markus T, Hansson SR, Cronberg T, et al. (2010) β-Adrenoceptor activation depresses brain inflammation and is neuroprotective in lipopolysaccharide-induced sensitization to oxygen-glucose deprivation in organotypic hippocampal slices. *J Neuroinflammation* 7: 94.
48. Cunningham M, Gilkeson G (2011) Estrogen receptors in immunity and autoimmunity. *Clin Rev Allergy Immunol* 40: 66–73.

49. Geserick C, Meyer HA, Haendler B (2005) The role of DNA response elements as allosteric modulators of steroid receptor function. *Mol Cell Endocrinol* 236: 1–7.

50. Li J, McMurray RW (2006) Effects of estrogen receptor subtype-selective agonists on immune functions in ovariectomized mice. *Int Immunopharmacol* 6: 1413–1423.

51. Li J, McMurray RW (2010) Effects of cyclic versus sustained estrogen administration on peripheral immune functions in ovariectomized mice. *Am J Reprod Immunol* 63: 274–281.

52. Delpy L, Douin-Echinard V, Garidou L, et al. (2005) Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. *J Immunol* 175: 5050–5057.

53. Murphy AJ, Guyre PM, Pioli PA (2010) Estradiol suppresses NF-kappa B activation through coordinated regulation of let-7a and miR-125b in primary human macrophages. *J Immunol* 184: 5029–5037.

54. Tiwari-Woodruff S, Voskuhl RR (2009) Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. *J Neurol Sci* 286: 81–85.

55. Hildebrand F, Hubbard WJ, Choudhry MA, et al. (2006) Are the protective effects of 17 beta-estradiol on splenic macrophages and splenocytes after trauma-haemorrhage mediated via estrogen-receptor (ER)-alpha or ER-beta? *J Leukoc Biol* 79: 1173–1180.

56. Kawasaki T, Suzuki T, Choudhry MA, et al. (2010) Salutary effects of 17 beta-estradiol on Peyer’s patch T cell functions following trauma-haemorrhage. *Cytokine* 51: 166–172.

57. Suzuki T, Yu HP, Hsieh YC, et al. (2008) Mitogen activated protein kinase (MAPK) mediates non-genomic pathway of estrogen on T cell cytokine production following trauma-haemorrhage. *Cytokine* 42: 32–38.

58. Liao ZH, Huang T, Xiao JW, et al. (2019) Estrogen signaling effects on muscle-specific immune responses through controlling the recruitment and function of macrophages and T cells. *Skeletal Muscle* 9: 20.

59. Khan D, Ansar Ahmed S (2015) The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases. *Front Immunol* 6: 635.

60. Spengler RN, Allen RM, Remick DG, et al. (1990) Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumour necrosis factor. *J Immunol* 145: 1430–1434.

61. Prossnitz ER, Barton M (2011) The G-protein-coupled estrogen receptor GPER in health and disease. *Nat Rev Endocrinol* 7: 715–726.

62. Bourque M, Dluzen DE, Di Paolo T (2012) Signalling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson’s disease. *Front Neuroendocrinol* 33: 169–178.

63. Lebesgue D, Chevaleyre V, Zuki RS, et al. (2009) Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of neuroprotection. *Steroids* 74: 555–561.

64. Thomas W, Coen N, Faherty S, et al. (2006) Estrogen induces phospholipase A2 activation through ERK1/2 to mobilize intracellular calcium in MCF-7 cells. *Steroids* 71: 256–265.
65. Titolo D, Mayer CM, Dhillon SS, et al. (2008) Estrogen facilitates both phosphatidylinositol 3-kinase/Akt and ERK1/2 mitogen-activated protein kinase membrane signalling required for long-term neuropeptide Y transcriptional regulation in clonal, immortalized neurons. *J Neurosci* 28: 6473–6482.
66. Milette S, Hashimoto M, Perrino S, et al. (2019) Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases. *Nat Commun* 10: 5745.
67. Wade CB, Dorsa DM (2003) Estrogen activation of cyclic adenosine 5'-monophosphate response element mediated transcription requires the extracellularly regulated kinase/mitogen-activated protein kinase pathway. *Endocrinology* 144: 832–838.
68. Fernandez SM, Lewis MC, Pechenino AS, et al. (2008) Estradiol-induced enhancement of object memory consolidation involves hippocampal ERK activation and membrane-bound estrogen receptors. *J Neurosci* 28: 6473–6482.
69. Carlstrom L, Ke ZJ, Unnerstall JR, et al. (2001) Estrogen modulation of the cyclic AMP response element-binding protein pathway. Effects of long-term and acute treatments. *Neuroendocrinology* 74: 227–243.
70. Grove-Strawser D, Boulware MI, Mermelstein PG (2010) Membrane estrogen receptors activate the metabotropic glutamate receptors mGluR5 and mGluR3 to bidirectionally regulate CREB phosphorylation in female rat striatal neurons. *Neuroscience* 170: 1045–1055.
71. Sanchez MG, Morissette M, Di Paolo T (2012) Effect of a chronic treatment with 17 β-estradiol on striatal dopamine neurotransmission and the Akt/GSK3 signalling pathway in the brain of ovariectomized monkeys. *Psychoneuroendocrinology* 37: 280–291.
72. Zhang QG, Wang R, Tang H, et al. (2014) Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus. *Mol Cell Endocrinol* 389: 84–91.
73. Pratap UP, Patil A, Sharma HR, et al. (2016) Estrogen-induced neuroprotective and anti-inflammatory effects are dependent on the brain areas of middle-aged female rats. *Brain Res Bull* 124: 238–253.
74. Maharjan S, Serova LI, Sabban EL (2010) Membrane-initiated estradiol signalling increases tyrosine hydroxylase promoter activity with ER alpha in PC12 cells. *J Neurochem* 112: 42–55.
75. Pendergast JS, Tuesta LM, Bethea JR (2008) Oestrogen receptor beta contributes to the transient sex difference in tyrosine hydroxylase expression in the mouse locus coeruleus. *J Neuroendocrinol* 20: 1155–1164.
76. Thanky NR, Son JH, Herbison AE (2002) Sex differences in the regulation of tyrosine hydroxylase gene transcription by estrogen in the locus coeruleus of TH9-LacZ transgenic mice. *Brain Res Mol Brain Res* 104: 220–226.
77. Yamaguchi N, Yuri K (2014) Estrogen-dependent changes in estrogen receptor-β mRNA expression in middle-aged female rat brain. *Brain Res* 1543: 49–57.
78. Foster TC (2012) Role of estrogen receptor alpha and beta expression and signalling on cognitive function during aging. *Hippocampus* 22: 656–669.
79. Coyoy-Salgado A, Segura-Uribe JJ, Manuel Gallardo J, et al. (2020) Tibolone regulates systemic metabolism and the expression of sex hormone receptors in the central nervous system of ovariectomised rats fed with high-fat and high-fructose diet. *Brain Res* 6: 1748.
80. Zoubina EV, Mize AL, Alper RH, et al. (2001) Acute and chronic estrogen supplementation decreases uterine sympathetic innervation in ovariectomized adult virgin rats. *Histol Histopathol* 16: 989–996.

81. Chisholm NC, Packard AR, Koss WA, et al. (2012) The Effects of Long-Term Treatment with Estradiol and Medroxyprogesterone Acetate on Tyrosine Hydroxylase Fibers and Neuron Number in the Medial Prefrontal Cortex of Aged Female Rats. *Endocrinology* 153: 4874–4882.

82. Kale P, Mohanty A, Patil A, et al. (2014) Estrogen modulates neural-immune interactions through intracellular signalling pathways and antioxidant enzyme activity in the spleen of middle-aged ovariectomized female rats. *J Neuroimmunol* 267: 7–15.

83. Tang MX, Jacobs D, Stern Y, et al. (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. *Lancet* 348: 429–432.

84. Jacome LF, Gautreaux C, Inagaki T, et al. (2010) Estradiol and ERβ agonists enhance recognition memory, and DPN, an ERβ agonist, alters brain monoamines. *Neurobiol Learn Mem* 94: 488–498.

85. Gibbs RB (2010) Estrogen therapy and cognition: a review of the cholinergic hypothesis. *Endocr Rev* 31: 224–253.

86. Norbury R, Cutter WJ, Compton J, et al. (2003) The neuroprotective effects of estrogen on the aging brain. *Exp Gerontol* 38: 109–117.

87. Paul V, Ekambaram P (2011) Involvement of nitric oxide in learning & memory processes. *Indian J Med Res* 133: 471–478.

88. Kopf SR, Benton RS, Kalfin R, et al. (2001) NO synthesis inhibition decreases cortical ACH release and impairs retention of conditioned response. *Brain Res* 894: 141–144.

89. Ghisletti S, Meda C, Maggi A, et al. (2005) 17 beta-estradiol inhibits inflammatory gene expression by controlling NF-kappa B intracellular localization. *Mol Cell Biol* 25: 2957–2968.

90. Walf AA, Paris JJ, Rhodes ME, et al. (2011) Divergent mechanisms for trophic actions of estrogens in the brain and peripheral tissues. *Brain Res* 1379: 119–136.

91. Hasan W, Smith HJ, Ting AY, et al. (2005) Estrogen alters trkA and p75 neurotrophin receptor expression within sympathetic neurons. *J Neurobiol* 65: 192–204.

92. Arbogast LA, Hyde JF (2000) Estradiol attenuates the forskolin-induced increase in hypothalamic tyrosine hydroxylase activity. *Neuroendocrinology* 71: 219–227.

93. Kritzer MF, Kohama SG (1998) Ovarian hormones influence the morphology, distribution, and density of tyrosine hydroxylase immunoreactive axons in the dorsolateral prefrontal cortex of adult rhesus monkeys. *J Comp Neurol* 395: 1–17.

94. Babu GN, Vijayan E (1984) Hypothalamic tyrosine hydroxylase activity and plasma gonadotropin and prolactin levels in ovariectomized-steroid treated rats. *Brain Res Bull* 12: 555–558.

95. Chisholm NC, Packard AR, Koss WA, et al. (2012) The effects of long-Term treatment with estradiol and medroxyprogesterone acetate on tyrosine hydroxylase fibers and neuron number in the medial prefrontal cortex of aged female rats. *Endocrinology* 153: 4874–4882.

96. Turciano P, Savica R (2020) Sex differences in movement disorders. *Handb Clin Neurol* 175: 275–282.
97. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med* 11: 81–128.

98. Viveros MP, Arranz L, Hernanz A, et al. (2007) A model of premature aging in mice based on altered stress-related behavioural response and immunosenescence. *Neuroimmunomodulation* 14: 157–162.

99. Tian L, Cai Q, Bowen R, et al. (1995) Effects of caloric restriction on age-related oxidative modifications of macromolecules and lymphocyte proliferation in rats. *Free Radic Biol Med* 19: 859–865.

100. Baeza I, Alvarado C, Alvarez P, et al. (2009) Improvement of leucocyte functions in ovariecotomised aged rats after treatment with growth hormone, melatonin, oestrogens or phyto-oestrogens. *J Reprod Immunol* 80: 70–79.

101. Baeza I, De Castro NM, Giménez-Llort L, et al. (2010) Ovariecotmy, a model of menopause in rodents, causes a premature aging of the nervous and immune systems. *J Neuroimmunol* 219: 90–99.

102. Baeza I, Fdez-Tresguerres J, Ariznavarreta C, et al. (2010) Effects of growth hormone, melatonin, oestrogens and phytoestrogens on the oxidized glutathione (GSSG)/reduced glutathione (GSH) ratio and lipid peroxidation in aged ovariecotomized rats. *Biogerontology* 11: 687–701.

103. Vina J, Gambini J, Lopez-Grueso R, et al. (2011) Females live longer than males: role of oxidative stress. *Curr Pharm Des* 17: 3959–3965.

104. Germain D (2016) Sirtuins and the Estrogen Receptor as Regulators of the Mammalian Mitochondrial UPR in Cancer and Aging. *Adv Cancer Res* 130: 211–256.

105. Brann D, Raz L, Wang R, et al. (2012) Oestrogen signalling and neuroprotection in cerebral ischaemia. *J Neuroendocrinol* 24: 34–47.

106. Simpkins JW, Green PS, Gridley KE, et al. (1997) Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer’s disease. *Am J Med* 103: 19S–25S.

107. Shulman GI, Barrett EJ, Sherwin RS (2003) Integrated fuel metabolism. In: Porte D, Sherwin RS, Baron A, Eds. *Ellenberg & Rifkin’s diabetes mellitus*, McGraw-Hill, New York, 1–13.

108. Shi J, Simpkins JW (1997) 17 beta-Estradiol modulation of glucose transporter 1 expression in blood-brain barrier. *Am J Physiol* 272: E1016–E1022.

109. Kostanyan A, Nazaryan A (1992) Rat brain glycolysis regulation by estradiol-17 beta. *Biochim Biophys Acta* 1133: 301–306.

110. Magistretti P (2008) Brain energy metabolism. In: Squire L, Bloom FE, Spitzer NC, Eds. *Fundamental neuroscience*, Academic, San Diego, 271–296.

111. Hernández-R J (1992) Na⁺/K⁺-ATPase regulation by neurotransmitters. *Neurochem Int* 20: 1–10.

112. Brinton RD (2008) Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer’s disease. *Adv Drug Deliv Rev* 60: 1504–1511.

113. Kostanyan A, Nazaryan A (1992) Rat brain glycolysis regulation by estradiol-17 beta. *Biochim Biophys Acta* 1133: 301–306.
114. Moorthy K, Yadav UC, Siddiqui MR, et al. (2004) Effect of estradiol and progesterone treatment on carbohydrate metabolizing enzymes in tissues of aging female rats. *Biogerontology* 5: 249–259.

115. Rasgon NL, Silverman D, Siddarth P, et al. (2005) Estrogen use and brain metabolic change in postmenopausal women. *Neurobiol Aging* 26: 229–235.

116. Monteiro R, Teixeira D, Calhau C (2014) Estrogen signaling in metabolic inflammation. *Mediators Inflamm* 2014: 615917.

117. Villa A, Rizzi N, Vegeto E, et al. (2015) Estrogen accelerates the resolution of inflammation in macrophagic cells. *Sci Rep* 5: 15224.

118. Bagger YZ, Tankó LB, Alexandersen P, et al. (2005) Early postmenopausal hormone therapy may prevent cognitive impairment later in life. *Menopause* 12: 12–7.

119. Maki PM (2006) Hormone therapy and cognitive function: is there a critical period for benefit? *Neuroscience* 138: 1027–1030.

120. Keller JN, Germeyer A, Begley JG, et al. (1997) 17 Beta-estradiol attenuates oxidative impairment of synaptic Na⁺/K⁺-ATPase activity, glucose transport, and glutamate transport induced by amyloid beta-peptide and iron. *J Neurosci Res* 50: 522–530.

121. Kumar P, Kale RK, McLean P, et al. (2011) Protective effects of 17 β- estradiol on altered age related neuronal parameters in female rat brain. *Neurosci Lett* 502: 56–60.

122. Shi C, Xu J (2008) Increased vulnerability of brain to estrogen withdrawal-induced mitochondrial dysfunction with aging. *J Bioenerg Biomembr* 40: 625–630.

123. Wong-Riley MT (1989) Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. *Trends Neurosci* 12: 94–101.

124. Bettini E, Maggi A (1992) Estrogen induction of cytochrome c oxidase subunit III in rat hippocampus. *J Neurochem* 58: 1923–1929.

125. Soane L, Kahraman S, Kristian T, et al. (2007) Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. *J Neurosci Res* 85: 3407–3415.

126. Atamna H, Frey WH (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease. *Mitochondrion* 7: 297–310.

© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)